Showing 3381-3390 of 5621 results for "".
- PolyActiva Initiates US Phase 2b Clinical Trial of PA5108 Biodegradable Ocular Implant for Glaucoma and OHThttps://modernod.com/news/polyactiva-enrolls-first-patient-in-us-phase-2b-clinical-trial-of-its-ocular-micro-implant-for-glaucoma-and-ocular-hypertension/2482925/PolyActiva announced the enrollment of the first US patient in its phase 2b clinical trial evaluating PA5108, a novel intracameral, biodegradable micro implant designed to provide sustained IOP reduction in patients with primary open-angle glaucoma (POAG)
- Mark Maire Appointed CEO of Rebionhttps://modernod.com/news/mark-maire-appointed-ceo-of-rebion/2482920/Rebion, a provider of neuro-visual diagnostics and digital retinal imaging technologies, announced the appointment of Mark Maire as Chief Executive Officer. Mr. Maire brings more than two decades of commercial leadership and strategic growth experience, including the sale of TrueVi
- Market Scope: Investor Interest in Ophthalmology Remains Stronghttps://modernod.com/news/market-scope-investor-interest-in-ophthalmology-remains-strong/2482919/The ophthalmic industry continues to command the attention of investors with $620 million raised across 13 transactions in Q2 2025, according to Market Scope’s latest Ophthalmic Deals Report. However, the investment dollars are down from Q2-2024 and
- Alcon to Acquire Staar Surgical for $1.5 Billionhttps://modernod.com/news/alcon-to-acquire-staar-surgical-for-15-billion/2482917/In a major deal to expand its refractive portfolio and continue its spree of acquisitions, Alcon has agreed to acquire Staar Surgical, maker of the Implantable Collamer Lens (ICL). The acquisition includes the EVO family of l
- Topcon Healthcare Acquires Intelligent Retinal Imaging Systemshttps://modernod.com/news/topcon-healthcare-acquires-intelligent-retinal-imaging-systems-to-enhance-connected-care-across-primary-and-eye-care/2482909/Topcon Healthcare announced the acquisition of Intelligent Retinal Imaging Systems (IRIS), a US-based provider of cloud-based retinal screening technology. FInancial terms of the deal were not disclosed. IRIS bri
- Alcon Announces US Launch of Tryptyr for Dry Eye Diseasehttps://modernod.com/news/alcon-announces-us-launch-of-tryptyr-for-dry-eye-disease/2482908/Alcon announced the US commercial availability of Tryptyr (acoltremon ophthalmic solution) 0.003% for the treatment of the signs and symptoms of dry eye disease (DED). Approved by the FDA in May, eye care professionals (ECPs) across the US can officially begin p
- EyePoint Completes Enrollment of Phase 3 Trials for Duravyu in Wet AMDhttps://modernod.com/news/eyepoint-completes-enrollment-of-phase-3-trials-for-duravyu-in-wet-amd/2482907/EyePoint Pharmaceuticals has completed enrollment of its phase 3 pivotal program with the full enrollment of the LUCIA trial, the second of two identical ongoing pivotal noninferiority trials evaluating Duravyu for the treatment of wet age-related macular degeneration (AMD). The first p
- Alcon Showcases Surgical Efficiency of Unity VCS Innovations at ASRS 2025https://modernod.com/news/alcon-showcases-surgical-efficiency-of-unity-vcs-innovations-at-asrs-2025/2482903/Alcon will showcase its latest clinical data and innovations at the 2025 American Society of Retina Specialists (ASRS) annual meeting, July 31 to August 2, in Long Beach, California. Attendees can explore Alcon’s latest surgical advancements through scientific presentations and hands-on dem
- Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindnesshttps://modernod.com/news/opus-genetics-and-the-global-rdh12-alliance-partner-to-advance-rdh12-gene-therapy-for-inherited-childhood-blindness/2482902/Opus Genetics announced a partnership with the Global RDH12 Alliance to advance Opus’ gene therapy program for patients with vision loss due to retinol dehydrogenase 12 (RDH12) gene mutations. The Alliance serves as a collaborative platform uniting advocacy groups dedicated to RDH
- Annexon Completes Enrollment in Phase 3 ARCHER II Trial of Vonaprument for GAhttps://modernod.com/news/annexon-completes-enrollment-in-phase-3-archer-ii-trial-of-vonaprument-for-ga/2482901/Annexon announced enrollment has been completed in the phase 3 ARCHER II trial of vonaprument (formerly ANX007) for dry age-related macular degeneration (AMD) with geographic atrophy (GA). The company remains on track to report topline data in the second half of 2026. Accordin